Track topics on Twitter Track topics that are important to you
SYDNEY, AUSTRALIA -- (Marketwired) -- 06/04/15 -- Prima BioMed Ltd (NASDAQ: PBMD) (ASX: PRR) ("Prima", the "Company"), announces that, further to the announcement made on 29 December 2014, it has received a notice, dated 3 June 2015 from the Listing Qualifications Department of The NASDAQ Stock Market, indicating that, for the 10 consecutive business days from 19 May 2015 to 2 June 2015, the closing bid price of the Company's American Depositary Shares has been at $1.00 per share or greater. Accordingly, the Company has regained compliance with Listing Rule 5450(a)(1) ("the Minimum Bid Price Rule") and the Company's shares will remain listed on The NASDAQ Global Market.
About Prima BioMed
Prima BioMed is a globally active biotechnology company that is striving to become a leader in the development of immunotherapeutic products for the treatment of cancer. Prima BioMed is dedicated to leveraging its technology and expertise to bring innovative treatment options to market for patients and to maximise value to shareholders.
Prima's original product, called CVac, is an ex vivo dendritic cell priming therapy that in May 2015 yielded favourable Phase II data in second remission ovarian cancer patients. Prima is currently seeking partners for further development of this therapy. Prima's current lead product is IMP321, based on the LAG-3 immune control mechanism which plays a vital role in the regulation of the T cell immune response. IMP321, which is soluble LAG-3, is a T cell immunostimulatory factor for cancer chemoimmunotherapy which has completed early Phase II trials. A number of additional LAG-3 products including antibodies for immune response modulation in autoimmunity and cancer are being developed by large pharmaceutical partners.
Prima BioMed is listed on the Australian stock exchange and on the NASDAQ in the US. For further information please visit www.primabiomed.com.auStuart Roberts Global Head of Investor Relations +61 (0) 447 247 909 Adam Holdsworth ProActive Capital +1 (646) 862 4607 Mr Matthew Gregorowski Citadel Communications +61 (0) 422 534 755 Mr. Axel Muhlhaus edicto GmbH +49 (0) 69 905505-52 NEXT ARTICLE
Antibodies Antisense Assays Biochips Bioinformatics Biological Therapy Biomarkers Biomaterials Bioscience Cell Culture Cloning Cytokine Diagnostics Dna Extraction Dna Sequencing Dna Transform...